Mechanisms of action of new oral coagulants

Abstract

The article provides a brief description of drugs in the class of direct oral anticoagulants. The mechanisms of the therapeutic effect and the ways of excretion of drugs-inhibitors of blood coagulation factors Xa and IIa are considered. It was shown that all of them are characterized by high selectivity to the active centers of target molecules, successfully affect the coagulation cascade and have a quick therapeutic effect. A comparative analysis of drugs of the class of direct oral anticoagulants showed that rivaroxaban, apixaban, edoxaban, betrixaban (inhibitors of FXa) and dabigatran (inhibitor of factor IIa) do not have significant advantages over each other in terms of mechanism and speed of action. A comparison of the main characteristics of direct oral anticoagulants and the indirect anticoagulant warfarin is presented. It is shown that, first of all, the advantage of the former is associated with an immediate pharmacological response. The decision to prescribe this drug requires consideration of risk factors for the patient, such as age, the presence of chronic diseases of the gastrointestinal tract, liver and kidneys. The article presents the most frequent complications of anticoagulant therapy, as well as the mechanisms of action of specific and universal antidotes indicated for use in patients with life-threatening bleeding or in need of urgent surgery when using direct oral anticoagulants. However, such neutralizing agents have not yet found widespread use due to their high cost and low availability. Nevertheless, the emergence of direct anticoagulants on the market has undoubtedly led to significant progress in the treatment of thrombotic and cardiovascular diseases (1 table, bibliography: 28 refs).

Keywords

andexanet alpha / anticoagulant therapy / apixaban / aripazine / betrixaban / dabigatran / DOACs / edoxaban / gastrointestinal bleeding / idarucizumab / rivaroxaban

References

[1] Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013;52(2):69–82. DOI: 10.1007/s40262-012-0030-9

[2] Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists // Clin. Pharmacokinet. 2013. Vol. 52, No. 2. P. 69–82. DOI: 10.1007/s40262-012-0030-9

[3] Bhanwra S, Ahluwalia K. The new factor Xa inhibitor: Apixaban. J Pharmacol Pharmacother. 2014;5(1):12–14. DOI: 10.4103/0976-500X.124409

[4] Bhanwra S., Ahluwalia K. The new factor Xa inhibitor: Apixaban // J. Pharmacol. Pharmacother. 2014. Vol. 5, No. 1. P. 12–14. DOI: 10.4103/0976-500X.124409

[5] Kvasnicka T, Malikova I, Zenahlikova Z, et al. Rivaroxaban – Metabolism, Pharmacologic Properties and Drug Interactions. Curr Drug Metab. 2017;18(7):636–642. DOI: 10.2174/1389200218666170518165443

[6] Kvasnicka T, Malikova I, Zenahlikova Z, et al. Rivaroxaban – Metabolism, Pharmacologic Properties and Drug Interactions // Curr. Drug. Metab. 2017. Vol. 18, No. 7. P. 636–642. DOI: 10.2174/1389200218666170518165443

[7] Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther. 2011;338(1):372–380. DOI: 10.1124/jpet.111.180240

[8] Gnoth M.J., Buetehorn U., Muenster U., Schwarz T., Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban // J. Pharmacol. Exp. Ther. 2011. Vol. 338, No. 1. P. 372–380. DOI: 10.1124/jpet.111.180240

[9] Wong PC, Pinto DJ, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis. 2011;31(4):478–492. DOI: 10.1007/s11239-011-0551-3

[10] Wong P.C., Pinto D.J., Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor // J. Thromb. Thrombolysis. 2011. Vol. 31, No. 4. P. 478–492. DOI: 10.1007/s11239-011-0551-3

[11] Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. Clin Pharmacokinet. 2019;58(10):1265–1279. DOI: 10.1007/s40262-019-00775-z

[12] Byon W., Garonzik S., Boyd R.A., Frost C.E. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review // Clin. Pharmacokinet. 2019. Vol. 58, No. 10. P. 1265–1279. DOI: 10.1007/s40262-019-00775-z

[13] Minor C, Tellor KB, Armbruster AL. Edoxaban, a Novel Oral Factor Xa Inhibitor. Ann Pharmacother. 2015;49(7):843–850. DOI: 10.1177/1060028015579426

[14] Minor C., Tellor K.B., Armbruster A.L. Edoxaban, a Novel Oral Factor Xa Inhibitor // Ann. Pharmacother. 2015. Vol. 49, No. 7. P. 843–850. DOI: 10.1177/1060028015579426

[15] Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743–753. DOI: 10.1177/0091270009351883

[16] Ogata K., Mendell-Harary J., Tachibana M., et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers // J. Clin. Pharmacol. 2010. Vol. 50, No. 7. P. 743–753. DOI: 10.1177/0091270009351883

[17] Lekura J, Kalus JS. Overview of betrixaban and its role in clinical practice. Am J Health Syst Pharm. 2018;75(15):1095–1102. DOI: 10.2146/ajhp170785

[18] Lekura J., Kalus J.S. Overview of betrixaban and its role in clinical practice // Am. J. Health Syst. Pharm. 2018. Vol. 75, No. 15. P. 1095–1102. DOI: 10.2146/ajhp170785

[19] Huisman MV, Klok FA. Pharmacological properties of betrixaban. Eur Heart J Suppl. 2018;20(Suppl E): E12–E15. DOI: 10.1093/eurheartj/suy016

[20] Huisman M.V., Klok F.A. Pharmacological properties of betrixaban // Eur. Heart J. Suppl. 2018. No. 20 (Suppl E). P. E12–E15. DOI: 10.1093/eurheartj/suy016

[21] 1Baker DE. Formulary Drug Review: Betrixaban. Hosp Pharm. 2018;53(1):29–37. DOI: 10.1177/0018578717739397

[22] Baker D.E. Formulary Drug Review: Betrixaban // Hosp. Pharm. 2018. Vol. 53, No. 1. P. 29–37. DOI: 10.1177/0018578717739397

[23] Padrini R. Clinical Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Patients with Renal Failure. Eur J Drug Metab Pharmacokinet. 2019;44(1):1–12. DOI: 10.1007/s13318-018-0501-y

[24] Padrini R. Clinical Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Patients with Renal Failure // Eur. J. Drug. Metab. Pharmacokinet. 2019. Vol. 44, No. 1. P. 1–12. DOI: 10.1007/s13318-018-0501-y

[25] Knauf F, Chaknos M, Perazella MA. Dabigatran and Kidney Disease: A Bad Combination. Clin J Am Soc Nephrol. 2013;8(9): 1591–1597.

[26] Knauf F., Chaknos M., Perazella M.A. Dabigatran and Kidney Disease: A Bad Combination // Clin. J. Am. Soc. Nephrol. 2013. Vol. 8, No. 9. P. 1591–1597.

[27] van Ryn J, Goss A, Hauel N, et al. The discovery of dabigatran etexilate. Front Pharmacol. 2013;4:12. DOI: 10.3389/fphar.2013.00012

[28] van Ryn J., Goss A., Hauel N., et al. The discovery of dabigatran etexilate // Front. Pharmacol. 2013. No. 4. P. 12. DOI: 10.3389/fphar.2013.00012

[29] Vorob’eva NM, Panchenko EP. Dabigatran etexilate – a new oral anticoagulant for the treatment of venous thromboembolic complications. Aterotromboz. 2014; 1: 50–58. (In Russ.)

[30] Воробьева Н.М., Панченко Е.П. Дабигатрана этексилат — новый пероральный антикоагулянт для лечения венозных тромбоэмболических осложнений // Атеротромбоз. 2014. № 1. C. 50–58.

[31] Kustos SA, Fasinu PS. Direct-Acting Oral Anticoagulants and Their Reversal Agents – An Update. Medicines (Basel). 2019;6(4):103. DOI: 10.3390/medicines6040103

[32] Kustos S.A., Fasinu P.S. Direct-Acting Oral Anticoagulants and Their Reversal Agents – An Update // Medicines (Basel). 2019. Vol. 6, No. 4. P. 103. DOI: 10.3390/medicines6040103

[33] Laroia ST, Morales S, Laroia AT. Beyond warfarin: The advent of new oral anticoagulants. Indian J Radiol Imaging. 2015;25(4):375–379.

[34] Laroia S.T., Morales S., Laroia A.T. Beyond warfarin: The advent of new oral anticoagulants // Indian J. Radiol. Imaging. 2015. Vol. 25, No. 4. P. 375–379.

[35] Mel’nik AA. New generation of direct oral anticoagulants – (dаbigatran and rivaroxaban) and their laboratory control. Laboratorna dіagnostika. 2017;1(79): 5–25. (In Russ.)

[36] Мельник А.А. Новое поколение прямых оральных антикоагулянтов – (дaбигатран и ривароксабан) и их лабораторный контроль // Лабораторна діагностика. 2017. № 1 (79). С. 15–25.

[37] Masotti L, Campanini M. Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics. The New Oral Anticoagulants in the Internal Medicine Clinical Practice. 2013;7(8):1–7.

[38] Masotti L., Campanini M. Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics // The New Oral Anticoagulants in the Internal Medicine Clinical Practice. 2013. Vol. 7, No. 8. P. 1–7.

[39] Petrov VI, SHatalova OV, Gorbatenko VS, Gerasimenko AS. Antidotes for direct oral anticoagulants. Lekarstvenny vestnik. 2020;3(79):23–28. (In Russ.)

[40] Петров В.И., Шаталова О.В., Горбатенко В.С., Герасименко А.С. Антидоты прямых оральных антикоагулянтов // Лекарственный вестник. 2020. № 3 (79). C. 23–28.

[41] Yavelov IS. Direct oral anticoagulant edoxaban in patients with nonvalvular atrial fibrillation: direct comparison with warfarin. Cardiology. 2020;60(8):124–129. DOI: 10.18087/cardio.2020.8.n1244

[42] Явелов И.С. Прямой пероральный антикоагулянт эдоксабан у больных с неклапанной фибрилляцией предсердий: результаты прямого сравнения с варфарином // Кардиология. 2020. T. 60, № 8. C. 124–129. DOI: 10.18087/cardio.2020.8.n1244

[43] Moroz EV, Karateev AE, Kryukov EV, Chernetsov VA. Gastrointestinal bleeding with the use of new oral anticoagulants: epidemiology, risk factors, treatment and prevention. Scientific and practical rheumatology. 2017;55(6):675–684. DOI: 10.14412/1995-4484-2017-675-684

[44] Мороз Е.В., Каратеев А.Е., Крюков Е.В., Чернецов В.А. Желудочно-кишечные кровотечения при использовании новых пероральных антикоагулянтов: эпидемиология, факторы риска, лечение и профилактика // Научно-практическая ревматология. 2017. T. 55, № 6. C. 675–684. DOI: 10.14412/1995-4484-2017-675-684

[45] Lin S, Wang Y, Zhang L, Guan W. Dabigatran must be used carefully: literature review and recommendations for management of adverse events. Drug Des Devel Ther. 2019;13:1527–1533.

[46] Lin S., Wang Y., Zhang L., Guan W. Dabigatran must be used carefully: literature review and recommendations for management of adverse events // Drug Des. Devel. Ther. 2019. No. 13. P. 1527–1533.

[47] Fareed J, Siddiqui F, Ramacciotti E, Tafur A. Antidotes for the new oral anticoagulant drugs! Vascular Investigation and Therapy. 2019;2(3):78–81.

[48] Fareed J., Siddiqui F., Ramacciotti E., Tafur A. Antidotes for the new oral anticoagulant drugs! // Vascular Investigation and Therapy. 2019. Vol. 2, No. 3. P. 78–81.

[49] Honore PM, David C, Attou R, et al. New alternative to antidotes for novel oral anticoagulants and ticagrelor in the case of severe bleeding. Crit Care. 2020;24(1):48. DOI: 10.1186/s13054-020-2760-7

[50] Honore P.M., David C., Attou R., et al. New alternative to antidotes for novel oral anticoagulants and ticagrelor in the case of severe bleeding // Crit. Care. 2020.Vol. 24, No. 1. P. 48. DOI: 10.1186/s13054-020-2760-7

[51] Thammatinno V. Specific antidotes for direct oral anticoagulants. Thai Bulletin of Pharmaceutical Sciences. 2021;16(2):61–70. DOI: 10.14456/tbps.2021.16

[52] Thammatinno V. Specific antidotes for direct oral anticoagulants // Thai Bulletin of Pharmaceutical Sciences. 2021. Vol. 16, No. 2. P. 61–70. DOI: 10.14456/tbps.2021.16

[53] Siegal DM, Connolly SJ. Idarucizumab for Dabigatran-Related Gastrointestinal Bleeds. Circulation. 2019;139(6):757–759. DOI: 10.1161/CIRCULATIONAHA.118.038460

[54] Siegal D.M., Connolly S.J. Idarucizumab for Dabigatran-Related Gastrointestinal Bleeds // Circulation. 2019. Vol. 139, No. 6. P. 757–759. DOI: 10.1161/CIRCULATIONAHA.118.038460

[55] Godier A, Martin AC. Specific Antidotes for Direct Oral Anticoagulant Reversal: Case Closed or Cold Case? Circulation. 2019;140(18):1445–1447. DOI: 10.1161/CIRCULATIONAHA.119.041687

[56] Godier A., Martin A.C. Specific Antidotes for Direct Oral Anticoagulant Reversal: Case Closed or Cold Case? // Circulation. 2019. Vol. 140, No. 18. P. 1445–1447. DOI: 10.1161/CIRCULATIONAHA.119.041687

RIGHTS & PERMISSIONS

Kokorina A.A., Sokolova M.O., Slizhov P.A.